Clinical Trial Detail

NCT ID NCT03681951
Title First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

triple-receptor negative breast cancer

lung non-small cell carcinoma

melanoma

Therapies

GSK3145095

GSK3145095 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.